Testimony to the FDA Peripheral and Central Nervous Systems Drugs Advisory Committee on Suvorexant
The U.S. Food and Drug Administration should not approve the latest sleep medicine suvorexant because the drug’s long-lasting risks – both to patients and the general public – outweigh any short-term benefits on sleep.